Literature DB >> 25391969

Tissue thioredoxin reductase-1 expression in astrocytomas of different grades.

Hasan Esen1, Fatih Erdi, Bulent Kaya, Bahadır Feyzioglu, Fatih Keskin, Lutfi Saltuk Demir.   

Abstract

Thioredoxin (Trx) is a redox active protein that regulates several physiological and biochemical functions, such as growth, apoptosis and cellular defense. The function of Trx itself is regulated by thioredoxin reductase (TrxR). Studies performed in a variety of human primary tumors have shown that thioredoxin reductase 1 (TrxR1) is overexpressed in tumoral tissues compared with corresponding normal tissues. This study was designed to determine the expression of TrxR1 in astrocytoma tissues of different World Health Organization (WHO) grades (grade I-IV). The proliferative (Ki-67) and apoptotic indices of the specimens were also investigated for correlation analysis. Astrocytoma tissues were extracted from the histopathological specimens of 40 patients. These samples included seven histologically normal brain tissues that served as a control group and ten tumoral samples for each grade of astrocytoma (grade I-IV). The histologically normal brain tissues were obtained from the non-tumoral portions of the pathological specimens of grade I (2 cases), grade II (2 cases), grade III (2 cases) and grade IV (1 case) astrocytomas. TrxR1 expression was evaluated using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunostaining. The proliferative and apoptotic indices of the specimens were investigated by Ki-67 immunostaining and TUNEL assay, respectively. TrxR1 expression, as assessed by qRT-PCR, increased significantly with astrocytoma grade (p = 0.01). The immunostaining intensity of TrxR1 in grade IV astrocytomas was significantly greater than that in the control tissue and all other astrocytoma grades (p < 0.001). Similarly, immunostaining intensity of TrxR1 in the grade III astrocytomas was significantly greater than that in the control group and grade I astrocytomas (p < 0.001). All astrocytoma tissues showed more intense staining in ascending grades, but the differences between grade I and the control, grade II and the control, grades II and I, grades III and II were not statistically significant (p > 0.05). Ki-67 index values increased significant in accordance with grade progression (p = 0.01). The apoptotic index values were not significantly different in any group (p > 0.05); however, the differences between grade IV and the control and between grades IV and I were statistically significant (p < 0.05). Expression of TrxR1, as assessed by both qRT-PCR and immunostaining, correlated highly with both the astrocytoma grade and Ki-67 index.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25391969     DOI: 10.1007/s11060-014-1661-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  22 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Antioxidant enzymes in oligodendroglial brain tumors: association with proliferation, apoptotic activity and survival.

Authors:  Sally Järvelä; Järvelä Sally; Helena Bragge; Bragge Helena; Niina Paunu; Paunu Niina; Timo Järvelä; Järvelä Timo; Leo Paljärvi; Paljärvi Leo; Hannu Kalimo; Kalimo Hannu; Pauli Helén; Helén Pauli; Vuokko Kinnula; Kinnula Vuokko; Ylermi Soini; Soini Ylermi; Hannu Haapasalo; Haapasalo Hannu
Journal:  J Neurooncol       Date:  2006-04       Impact factor: 4.130

3.  Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer.

Authors:  S Kakolyris; A Giatromanolaki; M Koukourakis; G Powis; J Souglakos; E Sivridis; V Georgoulias; K C Gatter; A L Harris
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas.

Authors:  Joon Hyuk Choi; Tae Nyeun Kim; Seongyong Kim; Suk-Hwan Baek; Jung Hye Kim; Seung Rock Lee; Jae-Ryong Kim
Journal:  Anticancer Res       Date:  2002 Nov-Dec       Impact factor: 2.480

6.  The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis.

Authors:  Sarah J Welsh; William T Bellamy; Margaret M Briehl; Garth Powis
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

7.  Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme.

Authors:  Judith M Ford; Wendy Seiferheld; Jeffrey R Alger; Genevieve Wu; Thyra J Endicott; Minesh Mehta; Walter Curran; See-Chun Phan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-06-08       Impact factor: 7.038

8.  Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide.

Authors:  A Yokomizo; M Ono; H Nanri; Y Makino; T Ohga; M Wada; T Okamoto; J Yodoi; M Kuwano; K Kohno
Journal:  Cancer Res       Date:  1995-10-01       Impact factor: 12.701

Review 9.  Thioredoxin redox control of cell growth and death and the effects of inhibitors.

Authors:  G Powis; D L Kirkpatrick; M Angulo; A Baker
Journal:  Chem Biol Interact       Date:  1998-04-24       Impact factor: 5.192

10.  Role of podocalyxin in astrocytoma: Clinicopathological and in vitro evidence.

Authors:  Tianxiang Huang; Xin Jin; Lei He; Mingyu Zhang; Jun Wu; Yanjin Wang; Jiasheng Fang
Journal:  Oncol Lett       Date:  2013-09-02       Impact factor: 2.967

View more
  7 in total

Review 1.  Targeting the methionine addiction of cancer.

Authors:  Joni C Sedillo; Vincent L Cryns
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

2.  Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer.

Authors:  Haiyong Zhang; Jing Wu; Jinqiu Yuan; Huafu Li; Yawei Zhang; Wang Wu; Wei Chen; Chunming Wang; Sijun Meng; Songyao Chen; Mingyu Huo; Yulong He; Changhua Zhang
Journal:  J Exp Clin Cancer Res       Date:  2021-08-19

3.  EF24 induces ROS-mediated apoptosis via targeting thioredoxin reductase 1 in gastric cancer cells.

Authors:  Peng Zou; Yiqun Xia; Weiqian Chen; Xi Chen; Shilong Ying; Zhiguo Feng; Tongke Chen; Qingqing Ye; Zhe Wang; Chenyu Qiu; Shulin Yang; Guang Liang
Journal:  Oncotarget       Date:  2016-04-05

4.  TXNRD1 Is an Unfavorable Prognostic Factor for Patients with Hepatocellular Carcinoma.

Authors:  Binsheng Fu; Wei Meng; Xiancheng Zeng; Hui Zhao; Wei Liu; Tong Zhang
Journal:  Biomed Res Int       Date:  2017-04-27       Impact factor: 3.411

5.  Compensatory combination of mTOR and TrxR inhibitors to cause oxidative stress and regression of tumors.

Authors:  Yiqun Xia; Jundixia Chen; Yun Yu; Fengjiao Wu; Xin Shen; Chenyu Qiu; Tingting Zhang; Lin Hong; Peisen Zheng; Rongrong Shao; Chenxin Xu; Fang Wu; Wei Chen; Congying Xie; Ri Cui; Peng Zou
Journal:  Theranostics       Date:  2021-02-25       Impact factor: 11.556

6.  Thioredoxin System Protein Expression Is Associated with Poor Clinical Outcome in Adult and Paediatric Gliomas and Medulloblastomas.

Authors:  Anqi Yao; Sarah J Storr; Khaled Al-Hadyan; Ruman Rahman; Stuart Smith; Richard Grundy; Simon Paine; Stewart G Martin
Journal:  Mol Neurobiol       Date:  2020-05-16       Impact factor: 5.590

7.  A thioredoxin reductase inhibitor ethaselen induces growth inhibition and apoptosis in gastric cancer.

Authors:  Wang Wu; Zhiying Yang; Xing Xiao; Tailai An; Bo Li; Jun Ouyang; Huafu Li; Chunming Wang; Yawei Zhang; Haiyong Zhang; Yulong He; Changhua Zhang
Journal:  J Cancer       Date:  2020-03-04       Impact factor: 4.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.